Halozyme Therapeutics, Inc. (HALO): Price and Financial Metrics


Halozyme Therapeutics, Inc. (HALO): $46.56

-1.00 (-2.10%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add HALO to Watchlist
Sign Up

Industry: Biotech


Ranked

of 493

in industry

HALO Stock Summary

  • Price to trailing twelve month operating cash flow for HALO is currently 116.02, higher than 95.74% of US stocks with positive operating cash flow.
  • HALO's price/sales ratio is 24.04; that's higher than the P/S ratio of 91.09% of US stocks.
  • Over the past twelve months, HALO has reported earnings growth of -346.9%, putting it ahead of merely 5.12% of US stocks in our set.
  • Stocks that are quantitatively similar to HALO, based on their financial statements, market capitalization, and price volatility, are MMX, LITE, QLYS, LSCC, and UTHR.
  • Visit HALO's SEC page to see the company's official filings. To visit the company's web site, go to www.halozyme.com.

HALO Stock Price Chart Interactive Chart >

Price chart for HALO

HALO Price/Volume Stats

Current price $46.56 52-week high $56.40
Prev. close $47.56 52-week low $19.36
Day low $46.11 Volume 720,138
Day high $49.21 Avg. volume 1,384,887
50-day MA $44.87 Dividend yield N/A
200-day MA $36.93 Market Cap 6.67B

Halozyme Therapeutics, Inc. (HALO) Company Bio


Halozyme Therapeutics is a biotechnology company focused on developing and commercializing novel oncology therapies that target the tumor microenvironment. The company was founded in 1998 and is based in San Diego, California.

HALO Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target: Forecasted Gain:
$46.56$0.58 -99%

Below please find a table outlining a discounted cash flow forecast for HALO, in which we model out valuation assuming a variety of terminal growth rates. To summarize, we found that Halozyme Therapeutics Inc ranked in the 4th percentile in terms of potential gain offered. We should note, though, that the most conservative analysis suggests this stock will yield negative results -- and thus may be a potential short opportunity. As for the metrics that stood out in our discounted cash flow analysis of Halozyme Therapeutics Inc, consider:

  • The compound growth rate in the free cash flow of Halozyme Therapeutics Inc over the past 3.01 years is -0.26%; that's higher than merely 7.7% of free cash flow generating stocks in the Healthcare sector.
  • The business' balance sheet reveals debt to be 6% of the company's capital (with equity being the remaining amount). Approximately only 19.46% of US stocks with free cash flow have a lower reliance on debt in their capital structure.
  • Halozyme Therapeutics Inc's effective tax rate, as measured by taxes paid relative to net income, is at 0 -- greater than only 24.6% of US stocks with positive free cash flow.


Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price
0%-99%
1%-99%
2%-99%
3%-99%
4%-99%
5%-99%

Want more companies with a valuation profile/forecast similar to that of Halozyme Therapeutics Inc? See ALC, CSTL, LNTH, PACB, and RHE.


HALO Latest News Stream


Event/Time News Detail
Loading, please wait...

HALO Latest Social Stream


Loading social stream, please wait...

View Full HALO Social Stream

Latest HALO News From Around the Web

Below are the latest news stories about Halozyme Therapeutics Inc that investors may wish to consider to help them evaluate HALO as an investment opportunity.

Halozyme Therapeutics (HALO) Down 19.3% Since Last Earnings Report: Can It Rebound?

Halozyme Therapeutics (HALO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Yahoo | March 25, 2021

Is Halozyme Therapeutics (HALO) A Smart Long-Term Buy?

Artisan Partners Limited Partnership, a high value-added investment management firm, published its ‘Artisan Small Cap Fund’ fourth quarter 2020 investor letter – a copy of which can be downloaded here. A return of 27.07% was recorded by its Investor Class: ARTSX, 27.14% by its Advisor Class: APDSX, and 27.15% by its Institutional Class: APHSX, in the […]

Yahoo | March 19, 2021

Halozyme Stock Joins The 80-Plus RS Rating Club

Halozyme Therapeutics shows rising price performance, earning an upgrade to its IBD Relative Strength Rating from 77 to 81.

Yahoo | March 17, 2021

Let's Take Another Look at Halozyme Therapeutics

HALO now looks like it can correct to the $34 to $30 area in the weeks ahead….HALO

The Street RealMoney | March 4, 2021

2 Overvalued Biotech Stocks Still Worth Buying

If you're like many investors, the answer is "yes" -- but if you aren't careful, being fixated on a high P/S ratio can lead you to miss out on some of the best growth stock opportunities. NexoBrid has already been proven safe and effective in phase 3 clinical trials, so it's approaching the final steps before obtaining regulatory approval in the U.S. It's already been authorized in the EU.

Yahoo | March 4, 2021

Read More 'HALO' Stories Here

HALO Price Returns

1-mo 5.51%
3-mo -2.33%
6-mo 49.76%
1-year 135.15%
3-year 146.87%
5-year 286.39%
YTD 9.01%
2020 140.89%
2019 21.19%
2018 -27.79%
2017 105.06%
2016 -42.99%

Continue Researching HALO

Want to see what other sources are saying about Halozyme Therapeutics Inc's financials and stock price? Try the links below:

Halozyme Therapeutics Inc (HALO) Stock Price | Nasdaq
Halozyme Therapeutics Inc (HALO) Stock Quote, History and News - Yahoo Finance
Halozyme Therapeutics Inc (HALO) Stock Price and Basic Information | MarketWatch


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 1.0058 seconds.